Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RLYB Rallybio Corp.

Post-Mkt 02-04 16:10:04 EST

0.5752

-0.0508

-8.12%

盘后0.5752

+0.00000.00%

16:00 EST

High0.6000	Low0.5592	Vol310.47K
Open0.6000	D1 Closing0.6260	Amplitude6.52%
Mkt Cap24.30M	Tradable Cap11.69M	Total Shares42.24M
T/O178.76K	T/O Rate1.53%	Tradable Shares20.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RLYB","market":"US","secType":"STK","nameCN":"Rallybio Corp.","latestPrice":0.5752,"timestamp":1770238800000,"preClose":0.626,"halted":0,"volume":310472,"hourTrading":{"tag":"盘后","latestPrice":0.5752,"preClose":0.5752,"latestTime":"16:00 EST","volume":151,"amount":86.85520000000001,"timestamp":1770238801902,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.08115015974440888,"floatShares":20316700,"shares":42243774,"eps":-0.316036,"marketStatus":"Post-Mkt","change":-0.0508,"latestTime":"02-04 16:10:04 EST","open":0.6,"high":0.6,"low":0.5592,"amount":178763.450246,"amplitude":0.065176,"askPrice":0.6165,"askSize":100,"bidPrice":0.561,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.316036,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770253200000},"marketStatusCode":4,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":0.626,"preHourTrading":{"tag":"盘前","latestPrice":0.61,"preClose":0.626,"latestTime":"09:15 EST","volume":6982,"amount":4254.70205192,"timestamp":1770214540492,"change":-0.016,"changeRate":-0.025559,"amplitude":0.043131},"postHourTrading":{"tag":"盘后","latestPrice":0.5752,"preClose":0.5752,"latestTime":"16:00 EST","volume":151,"amount":86.85520000000001,"timestamp":1770238801902,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.97588},"requestUrl":"/m/hq/s/RLYB","defaultTab":"news","newsList":[{"id":"2608980011","title":"BRIEF-Rallybio Announces Reverse Stock Split Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2608980011","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608980011?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:06","pubTimestamp":1770152767,"startTime":"0","endTime":"0","summary":"BRIEF-Rallybio Announces Reverse Stock Split Of Common StockFeb 3 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES REVERSE STOCK SPLIT OF COMMON STOCKRALLYBIO CORP - TO EFFECT ONE-FOR-EIGHT REVERSE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA5ZVFLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RLYB"],"gpt_icon":0},{"id":"2608187800","title":"Rallybio führt Aktiensplit im Verhältnis 1:8 durch","url":"https://stock-news.laohu8.com/highlight/detail?id=2608187800","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608187800?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152715,"startTime":"0","endTime":"0","summary":"Die Rallybio Corporation führt einen Reverse Stock Split im Verhltnis 1:8 durch. Die Manahme tritt am 6. Februar 2026 in Kraft und soll den Aktienkurs anheben, um die Anforderungen für die Notierung am Nasdaq Capital Market zu erfüllen. Die Aktie wird weiterhin unter dem Kürzel \"RLYB\" gehandelt. Fractional Shares werden in bar abgegolten.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL8pY1X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4539","BK4139"],"gpt_icon":0},{"id":"2608935800","title":"Rallybio Corp - to Effect One-for-Eight Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2608935800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608935800?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA5ZVFLF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RLYB","BK4139"],"gpt_icon":0},{"id":"2607052245","title":"Rallybio Shareholders Approve Reverse Stock Split Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2607052245","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607052245?lang=en_us&edition=fundamental","pubTime":"2026-01-30 06:34","pubTimestamp":1769726082,"startTime":"0","endTime":"0","summary":"Rallybio ( ($RLYB) ) has provided an announcement. On January 26, 2026, Rallybio Corporation’s stockholders approved an amendment to its Certificat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybio-shareholders-approve-reverse-stock-split-amendment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybio-shareholders-approve-reverse-stock-split-amendment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2607547940","title":"Rallybio Corporation Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2607547940","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607547940?lang=en_us&edition=fundamental","pubTime":"2026-01-30 06:15","pubTimestamp":1769724929,"startTime":"0","endTime":"0","summary":"Rallybio Corporation held a special meeting of stockholders on January 26, 2026. Stockholders voted to approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the company's issued and outstanding common stock at a ratio ranging from 1-for-5 shares up to 1-for-20 shares, with the final ratio to be selected by the board of directors. The proposal was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL8ZZ19T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RLYB"],"gpt_icon":0},{"id":"2603363621","title":"Rallybio Terminates Phase 2 FNAIT Pregnancy Study: What Investors Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2603363621","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603363621?lang=en_us&edition=fundamental","pubTime":"2026-01-14 00:30","pubTimestamp":1768321823,"startTime":"0","endTime":"0","summary":"Rallybio Corporation ($RLYB) announced an update on their ongoing clinical study. Rallybio’s latest update centers on a Phase 2, multicenter, open-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybio-terminates-phase-2-fnait-pregnancy-study-what-investors-need-to-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybio-terminates-phase-2-fnait-pregnancy-study-what-investors-need-to-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4211","BK4139","RLYB","BK4539"],"gpt_icon":0},{"id":"2602308854","title":"Rallybio’s Phase 2 FNAIT Prevention Study Reaches Completion: What Investors Should Watch Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2602308854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602308854?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:30","pubTimestamp":1767976216,"startTime":"0","endTime":"0","summary":"Rallybio Corporation ($RLYB) announced an update on their ongoing clinical study. Study Overview: Rallybio Corporation (RLYB) has completed a Phase...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybios-phase-2-fnait-prevention-study-reaches-completion-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybios-phase-2-fnait-prevention-study-reaches-completion-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4211","BK4139","RLYB","BK4539"],"gpt_icon":0},{"id":"2593750448","title":"Rallybio Corporation Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2593750448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593750448?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:02","pubTimestamp":1766523744,"startTime":"0","endTime":"0","summary":"Rallybio Corporation will hold a Special Meeting of Stockholders on January 26, 2026. The meeting will take place in New Haven, Connecticut. Stockholders will consider the business set forth by the Board of Directors, as well as any other matters that may properly come before the meeting. Preliminary voting results will be announced at the meeting, with final results to be reported in a subsequent Form 8-K filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL4s41r7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2581020572","title":"Rallybio Corporation Reports Strong Q3 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581020572","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581020572?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:27","pubTimestamp":1762493244,"startTime":"0","endTime":"0","summary":"Rallybio Corporation ( ($RLYB) ) has released its Q3 earnings. Here is a breakdown of the information Rallybio Corporation presented to its investo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybio-corporation-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybio-corporation-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","RLYB"],"gpt_icon":0},{"id":"2581094614","title":"UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581094614","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581094614?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:35","pubTimestamp":1762439705,"startTime":"0","endTime":"0","summary":"Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 34.58 percent. This is a 46.15 percent increase over losses of $(0.26) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48687033/update-rallybio-q3-adj-eps-0-14-beats-0-21-estimate-sales-212-000k-beat-66-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB"],"gpt_icon":0},{"id":"2581509362","title":"Rallybio posts Q3 net income of $16 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581509362","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581509362?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:03","pubTimestamp":1762434223,"startTime":"0","endTime":"0","summary":"Rallybio Corporation reported a net income of $16.0 million, or $0.36 per common share, for the third quarter of 2025, compared to a net loss of $11.5 million, or $0.26 per common share, for the same period in 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $59.3 million. During the quarter, Rallybio generated $20.0 million from the sale of its interest in REV102 to Recursion Pharmaceuticals. The company advanced its lead program, RLYB116, with the completion of dosing in Cohort 1 of its confirmatory Phase 1 study, and expects to report data from the second cohort in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content us","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL807x3b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","RLYB","BK4139","BK4539","BK4611","BK4609"],"gpt_icon":1},{"id":"2581098070","title":"BRIEF-Rallybio Q3 Net Income USD 16.016 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581098070","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581098070?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434047,"startTime":"0","endTime":"0","summary":"BRIEF-Rallybio Q3 Net Income USD 16.016 Million\n\n\nNov 06 (Reuters) - Rallybio Q3 operating expenses USD 7.137 million.\n\nQ3 income from operations USD -6.925 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX14905D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RLYB"],"gpt_icon":0},{"id":"2581093253","title":"Rallybio Corp - Cash Runway Extended Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093253?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX14905D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2581093212","title":"Rallybio Corp -  Net Loss $0.36 per Common Share for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093212?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX14905D:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RLYB","BK4539"],"gpt_icon":0},{"id":"2578075627","title":"Rallybio’s RLYB116 Study: A Potential Game-Changer in Hematologic and Autoimmune Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578075627","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578075627?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:12","pubTimestamp":1761592334,"startTime":"0","endTime":"0","summary":"Rallybio Corporation (($RLYB)) announced an update on their ongoing clinical study. Rallybio Corporation is conducting a clinical study titled ‘Mul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybios-rlyb116-study-a-potential-game-changer-in-hematologic-and-autoimmune-disease-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybios-rlyb116-study-a-potential-game-changer-in-hematologic-and-autoimmune-disease-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","RLYB","BK4139"],"gpt_icon":0},{"id":"2570702094","title":"Rallybio Completes Dosing of First Cohort in Rlyb116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2570702094","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570702094?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:00","pubTimestamp":1758801646,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nFWN3VC16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0},{"id":"2570092887","title":"Rallybio Corp: Data Readouts for Completed Study Expected in 4Q 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2570092887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570092887?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:00","pubTimestamp":1758801646,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nFWN3VC16J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RLYB","BK4539"],"gpt_icon":0},{"id":"2564398785","title":"Rallybio Receives $12.5 Million Equity Milestone Payment From Recursion for Advancement of REV102 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398785?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:01","pubTimestamp":1756900882,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UP12U:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4539","BK4139"],"gpt_icon":0},{"id":"2564398202","title":"Rallybio Corp  -","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398202?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:01","pubTimestamp":1756900882,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UP12U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RLYB","BK4539"],"gpt_icon":0},{"id":"2564398087","title":"Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398087?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:01","pubTimestamp":1756900871,"startTime":"0","endTime":"0","summary":"Rallybio Corporation Announces Initiation of Additional Preclinical Studies for REV102, Secures $12.5 Million Milestone Payment from Recursion. Rallybio Corporation, a clinical-stage biotechnology company, has announced the receipt of a $12.5 million equity milestone payment from Recursion. This payment was triggered by the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor aimed at treating hypophosphatasia . The milestone payment extends Rallybio's cash runway through 2027. The company is looking forward to sharing topline data from the confirmatory PK/PD study of RLYB116 in the coming months. Results for the REV102 program have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL767vCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4139","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rallybio.com","stockEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.1149},{"period":"3month","weight":0.0013},{"period":"6month","weight":0.225},{"period":"1year","weight":-0.2792},{"period":"ytd","weight":-0.0876}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.05452},{"month":2,"riseRate":0.4,"avgChangeRate":0.114984},{"month":3,"riseRate":0,"avgChangeRate":-0.234376},{"month":4,"riseRate":0.5,"avgChangeRate":-0.025587},{"month":5,"riseRate":0.5,"avgChangeRate":0.132316},{"month":6,"riseRate":0.25,"avgChangeRate":-0.189526},{"month":7,"riseRate":1,"avgChangeRate":0.176338},{"month":8,"riseRate":0.4,"avgChangeRate":-0.034234},{"month":9,"riseRate":0.6,"avgChangeRate":0.045433},{"month":10,"riseRate":0.6,"avgChangeRate":0.040053},{"month":11,"riseRate":0.2,"avgChangeRate":-0.230437},{"month":12,"riseRate":0.6,"avgChangeRate":0.001492}],"exchange":"NASDAQ","name":"Rallybio Corp.","nameEN":"Rallybio Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rallybio Corp.,RLYB,Rallybio Corp.股票,Rallybio Corp.股票老虎,Rallybio Corp.股票老虎国际,Rallybio Corp.行情,Rallybio Corp.股票行情,Rallybio Corp.股价,Rallybio Corp.股市,Rallybio Corp.股票价格,Rallybio Corp.股票交易,Rallybio Corp.股票购买,Rallybio Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}